Novartis AG (ADR) news

   Watch this stock
Showing stories 1 - 10 of about 144   

Articles published

NVS 102.46 -0.85 (-0.82%)
price chart
Teva Pharmaceutical Industries (TEVA) Falls On FDA Approval For Novartis AG ...
The generic Copaxone, which has received approval for 20 mg strength, has been developed by Sandoz, the generic drug-making subsidiary of Novartis AG (ADR) (NYSE:NVS). The generic version has been labeled as a ´┐Żsubstitutable´┐Ż drug for Copaxone, ...
Gender Discrimination Lawsuit Filed Against Novartis AG (ADR)(NYSE:NVS)
There are various allegations of Sexual discrimination against Novartis AG (ADR) (NYSE:NVS)and it will have to defend itself against them in US courts.
Novartis AG (ADR) (NVS)'s Arzerra In Combination With Chlorambucil Shows 71 ...
Patients suffering with chronic lymphocytic leukemia (CLL) have a hope, in chemotherapy combination drugs Arzerra, and chlorambucil.
Novartis AG (ADR) (NVS) And Juno Therapeutics Inc (JUNO) Reach Mutual ...
Novartis AG (ADR) (NYSE:NVS) and Juno Therapeutics Inc (NASDAQ:JUNO) have reached a settlement to their long-running patent war.
Novartis AG (ADR) To Pay $12.3 Million To Juno In CAR-T Patent Settlement  Bidness ETC
Novartis AG (ADR) (NYSE:NVS) in Cancer Lawsuits and Alliances: Big Pharma ...
Novartis AG (ADR) (NYSE:NVS) recently settled a 3-year patent lawsuit over use of cancer therapeutics including the chimeric antigen receptor T-Cell (CART) technology.
Asset Swaps Of Novartis AG (ADR) (NYSE:NVS) and GlaxoSmithKline plc (ADR ...
An Announcement regarding the completion of a range of asset swaps was made concerning two significant companies, GlaxoSmithKline plc (ADR) (NYSE:GSK) and Novartis AG (ADR) (NYSE:NVS). These asset swaps tended to be a bit complex and were ...
GlaxoSmithKline plc (ADR) And Novartis AG (ADR) Complete Three-Part Deal ...  Bidness ETC
GSK deal's done. Now, Novartis has to deliver on cancer-growth pledge  FiercePharma
Novartis AG ADR (NVS): New Analyst Report from Zacks Equity Research ...
We are impressed by Novartis' efforts to realign its portfolio in order to focus on its core portfolio of pharmaceuticals, eye care and generics. The agreement to acquire oncology products from Glaxo will further broaden Novartis' portfolio, enable it ...
Related articles »  
Trade of the Day: Pullback in NVS Stock Could Yield 15%-Plus Profits
Novartis AG (ADR) (NYSE:NVS) - This Switzerland-based health care company is a leading international provider of pharmaceuticals, generic drugs, and consumer and animal health products.
Stock To Watch : Novartis AG (ADR)(NYSE:NVS)
Novartis AG (ADR)(NYSE:NVS) (TREND ANALYSIS) shares are still trading near the 52-week high of $102.59. The stock closed last trading session at $101.48, with a volume of 1,334,174 shares against an average volume for the last 3 months of 1,498,780.
BMJ Says Novartis AG (ADR) Hindered Trials That Pitted Lucentis Against ...
Novartis AG (ADR) (NYSE:NVS) has been accused of thwarting publicly-funded UK-based trials that attempted to test the safety and efficacy of Avastin, a cheaper potential alternative therapy, to Novartis' eye drug Lucentis for the treatment of wet age ...